Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Details - CS2009 is a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, and is set to undergo a Phase II clinical trial for advanced solid tumors [1] - The Phase II global multi-center clinical trial is actively recruiting in Australia and China, encompassing 15 monotherapy/combo therapy cohorts and 9 solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] Group 2: Preliminary Data and Future Expectations - Preliminary data from the Phase I clinical study of CS2009 has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) meetings [1] - The CEO of the company expressed satisfaction with the efficient progress of the Phase II clinical trial and highlighted the positive communication with the FDA regarding the drug's performance in the Phase I trial [2]
基石药业-B(02616)CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验申请获美国FDA批准